Bartoli Giulia, Dello Strologo Andrea, Arena Maria, Galeandro Egidio, Ferro Martina, Diomedi-Camassei Francesca, Pesce Francesco, Grandaliano Giuseppe
Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Roma, Italy.
Unit of Nephrology, Dialysis and Transplantation, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Roma, Italy.
Am J Case Rep. 2024 Dec 4;25:e944208. doi: 10.12659/AJCR.944208.
BACKGROUND Kidney transplantation is the optimal treatment for end-stage kidney disease. Over the last decades, the long-term survival of renal allografts has significantly increased. Nevertheless, several causes, including the recurrence of native kidney disease, can impair the allograft function over time. C3 glomerulopathy (C3GN) is a rare disease, characterized by an abnormal activation of the alternative complement pathway that leads to the accumulation of C3 complement component in the glomeruli. C3GN frequently recurs after kidney transplantation during the first years, leading to graft failure. Recently, during the Covid-19 pandemic, the outcome of kidney transplant patients generally worsened, and several studies showed the effects of SARS-CoV-2 infection on renal function. CASE REPORT Here, we present the clinical case of a female kidney transplant recipient whose renal function worsened after 28 years of transplantation concurrently with two SARS-CoV-2 infections (in October 2020 and March 2022). In 1994, the patient received a diagnosis of acute post-infectious glomerulonephritis, leading to end-stage kidney disease and a living-donor kidney. The most recent allograft biopsy and laboratory test results showed chronic rejection and features of C3GN. Thus, given the possibility of a recurrent glomerulopathy, we reanalyzed the previous patient's renal biopsies performed in 1982 and 1988 and found that both suggested C3GN. CONCLUSIONS Based on these data and the current evidence, we could conclude that in this case, C3GN occurred as a late recurrence disease caused by complement activation after SARS-CoV-2 infection.
肾移植是终末期肾病的最佳治疗方法。在过去几十年中,同种异体肾移植的长期存活率显著提高。然而,包括原发病复发在内的多种原因会随着时间的推移损害移植肾功能。C3肾小球病(C3GN)是一种罕见疾病,其特征是替代补体途径异常激活,导致补体C3成分在肾小球中积聚。C3GN在肾移植后的最初几年经常复发,导致移植肾失功。最近,在新冠疫情期间,肾移植患者的预后普遍恶化,多项研究显示了严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染对肾功能的影响。病例报告:在此,我们报告一例女性肾移植受者的临床病例,该患者在肾移植28年后肾功能恶化,同时发生了两次SARS-CoV-2感染(2020年10月和2022年3月)。1994年,该患者被诊断为急性感染后肾小球肾炎,导致终末期肾病并接受了活体供肾肾移植。最近的移植肾活检和实验室检查结果显示为慢性排斥反应及C3GN特征。因此,鉴于存在肾小球病复发的可能性,我们重新分析了该患者在1982年和1988年进行的肾活检,发现两者均提示C3GN。结论:基于这些数据和现有证据,我们可以得出结论,在该病例中,C3GN是由SARS-CoV-2感染后补体激活引起的迟发性复发性疾病。